The efficacy of oral adenosine A2Aantagonist istradefylline for the treatment of moderate to severe Parkinson’s disease
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The efficacy of oral adenosine A2Aantagonist istradefylline for the treatment of moderate to severe Parkinson’s disease
Authors
Keywords
-
Journal
Expert Review of Neurotherapeutics
Volume 15, Issue 12, Pages 1383-1390
Publisher
Informa UK Limited
Online
2015-12-03
DOI
10.1586/14737175.2015.1113131
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease
- (2015) Tomoyoshi Kondo et al. CLINICAL NEUROPHARMACOLOGY
- The safety of istradefylline for the treatment of Parkinson’s disease
- (2015) Thomas Müller Expert Opinion On Drug Safety
- Istradefylline is Recommended for Morning Use: A Report of 4 Cases
- (2015) Keita Matsuura et al. INTERNAL MEDICINE
- Characterization in Humans of 18F-MNI-444, a PET Radiotracer for Brain Adenosine 2A Receptors
- (2015) O. Barret et al. JOURNAL OF NUCLEAR MEDICINE
- Efficacy of Adenosine A2A Receptor Antagonist Istradefylline as Augmentation for Parkinson’s Disease: A Meta-analysis of Randomized Controlled Trials
- (2014) Yingqun Tao et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued
- (2014) Annalisa Pinna CNS DRUGS
- Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant
- (2014) Santiago Perez-Lloret et al. EXPERT OPINION ON PHARMACOTHERAPY
- Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial
- (2014) Robert A Hauser et al. LANCET NEUROLOGY
- Adenosine A2A receptor antagonists in Parkinson's disease: still in the running
- (2014) Angelo Antonini et al. LANCET NEUROLOGY
- Abnormal functional connectivity of the amygdala is associated with depression in Parkinson's disease
- (2014) Xiao Hu et al. MOVEMENT DISORDERS
- Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease
- (2014) Stefka Gyoneva et al. NEUROBIOLOGY OF DISEASE
- Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson’s disease: a meta-analysis
- (2014) Chuan Zhu et al. NEUROLOGICAL RESEARCH
- Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats
- (2014) Koji Yamada et al. PSYCHOPHARMACOLOGY
- Istradefylline: First Global Approval
- (2013) Rosselle Dungo et al. DRUGS
- Adenosine A2Areceptor antagonist istradefylline reduces daily OFF time in Parkinson's disease
- (2013) Yoshikuni Mizuno et al. MOVEMENT DISORDERS
- Istradefylline, an adenosine A2A receptor antagonist, for patients with Parkinson's Disease: A meta-analysis
- (2012) Wanqiang Chen et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials
- (2012) Lorraine V. Kalia et al. MOVEMENT DISORDERS
- Future Treatments for Parkinson's Disease: Surfing the PD Pipeline
- (2011) Robert A. Hauser INTERNATIONAL JOURNAL OF NEUROSCIENCE
- Population Pharmacokinetic-Pharmacodynamic Analysis of Istradefylline in Patients With Parkinson Disease
- (2011) William Knebel et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
- (2011) Robert A Hauser et al. LANCET NEUROLOGY
- Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW-6002-US-018 study
- (2011) Emmanuelle Pourcher et al. PARKINSONISM & RELATED DISORDERS
- Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson's Disease Patients
- (2011) Masahiro Mishina et al. PLoS One
- Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study
- (2010) Fabrizio Stocchi et al. ANNALS OF NEUROLOGY
- Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study
- (2010) Yoshikuni Mizuno et al. MOVEMENT DISORDERS
- A long-term study of istradefylline in subjects with fluctuating Parkinson's disease
- (2010) Stewart Factor et al. PARKINSONISM & RELATED DISORDERS
- Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms
- (2009) Maria C Rodriguez-Oroz et al. LANCET NEUROLOGY
- Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial
- (2009) H.H. Fernandez et al. PARKINSONISM & RELATED DISORDERS
- Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)
- (2008) Peter A. LeWitt et al. ANNALS OF NEUROLOGY
- Adenosine A2Areceptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms
- (2008) Liqun Yu et al. ANNALS OF NEUROLOGY
- Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
- (2008) Robert A. Hauser et al. MOVEMENT DISORDERS
- Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
- A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
- (2008) M. Stacy et al. NEUROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started